Discontinuation versus continuation of antiarrhythmic drugs prior to pulmonary vein isolation for atrial fibrillation and influence on dormant conduction with adenosine; a randomised controlled trial.
Completed
- Conditions
- A-Fib10007521Atrial Fibrillation
- Registration Number
- NL-OMON42401
- Lead Sponsor
- Medisch Spectrum Twente
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 188
Inclusion Criteria
Adults
Atrial fibrillation greater or equal to EHRA class II accepted for pulmonary vein isolation according to current guidelines
Using class I or class III antiarrythmic drugs with exception of amiodaron (e.g. flecainide, sotalol)
Willing and able to sign informed consent
Exclusion Criteria
Usage of amiodaron (due to very long half life time(20-100 days) these patients will be excluded)
Prior PVI or MAZE
Severe asthmatic condition or contra indication for adenosine
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Incidence of dormant conduction with adenosine challenge after initial<br /><br>successful PVI. </p><br>
- Secondary Outcome Measures
Name Time Method <p>1. Incidence of AF prior to PVI.<br /><br>2. Recurrence of AF within 12 months of the procedure on ECG or >30 seconds on<br /><br>Holter/Vitaphone (With applied blanking period of 3 months) </p><br>